|
|
|
|
Type 2 Diabetes Risk Factors: New findings reported from A.M. Abbatecola and co-authors describe advances in type 2 diabetes risk factors
Today's Medical & Research News New findings reported from A.M.Abbatecola and co-authors describe advances in risk factors March 20th, 2010 Printer-Friendly Version City:Ancona Country:Italy Cognitive Disorders Dipeptidyl Peptidase Drugs Endocrinology...
|
|
|
NexMed Reports the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in Slow Release Form
(Close-Up Media via COMTEX) -- NexMed, Inc., a specialty CRO and a developer of products based on the NexACT technology, has announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated...
|
|
|
Liraglutide (Victoza): A GLP-1 analog approved for the treatment of type 2 diabetes
Liraglutide is the second glucagon-like peptide-1 (GLP-1) analog to gain FDA-marketing approval (January 25, 2010), and is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.Exenatide was...
|
|
|
NexACT shows preclinical SR potential
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release depot for drugs like insulin and taxol.The findings, based on rodent studies conducted by NexMeds recently acquired Bio-Quant unit,...
|
|
|
NexACT shows preclinical SR potential
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release depot for drugs like insulin and taxol.The findings, based on rodent studies conducted by NexMeds recently acquired Bio-Quant unit,...
|
|
|
Liraglutide (Victoza): A GLP-1 analog approved for the treatment of type 2 diabetes
Liraglutide is the second glucagon-like peptide-1 (GLP-1) analog to gain FDA-marketing approval (January 25, 2010), and is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.Exenatide was...
|
|
|
Novo Nordisk diabetes drug launch in US tops expectations, paper says
- The launch of type 2 diabetes drug Victoza in the USA by Danish pharma company Novo Nordisk A/S (CPH: NOVO B) is progressing better than expected, Danish daily Dagbladet Borsen said Friday."The penetration of Byetta was quite good at the beginning, so this...
|
|
|
NexACT shows preclinical SR potential
CRO NexMed says new data from preclinical trials show that its NexACT delivery technology can act as a sustained release depot for drugs like insulin and taxol.The findings, based on rodent studies conducted by NexMeds recently acquired Bio-Quant unit,...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-L
SAN DIEGO(BUSINESS WIRE) NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully...
|
|
|
NexACT technology demonstrates ability to deliver Taxol subcutaneously
NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability...
|
|
|
Roche delivers updated pipeline
Roche says its pipeline can sustain its growth in oncology and increase its presence in personalised healthcare.Roche also plans to further expand into therapeutic areas such as metabolism, inflammation and diseases of the central nervous system. Roches...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot
NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have...
|
|
|
NexMed Announces the Ability of Its NexACT(R) Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
(BUSINESS WIRE) ----NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT(R) technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
SAN DIEGONexMed, Inc.(Nasdaq Specifically, rodents that received insulin injections incorporating the NexACT technology showed bio-equivalency to Lantus in controlling glucose levels in the blood. Further studies in rodents showed that NexACT was able to...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
SAN DIEGONexMed, Inc.(Nasdaq Specifically, rodents that received insulin injections incorporating the NexACT technology showed bio-equivalency to Lantus in controlling glucose levels in the blood. Further studies in rodents showed that NexACT was able to...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
Companies mentioned in this article: NexMed, Inc.SAN DIEGO -- (BUSINESS WIRE) -- NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
SAN DIEGO - (Business Wire) NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have...
|
|
|
NexMed Announces the Ability of Its NexACT(R) Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
SAN DIEGO--(BUSINESS WIRE)-- NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT(R) technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability...
|
|
|
NexMed Announces the Ability of Its NexACT Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion
NexMed, Inc.(Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability...
|
|
|
Amylin, Lilly And Alkermes Receive Complete Response Letter From FDA For Exenatide Once Weekly Submission
Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for...
|
|
|
FDA questions delay long-acting Byetta
A once-weekly formulation of Eli Lilly and Amylin Pharmaceuticals' blockbuster diabetes medication Byetta has hit a manufacturing hurdle en route to the registration in the US.The FDA has sent the two companies a response letter indicating that there are...
|
|
|
Amylin, Lilly & Alkermes get US FDA complete response letter for exenatide ER
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc.announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for Bydureon (exenatide for extended-release...
|
|
|
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
BYDUREON(TM) (exenatide for extended-release injectable suspension) Proposed Name SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., March 15, 2010 (HSMN NewsFeed) -- Amylin Pharmaceuticals, Inc.(Nasdaq:AMLN ), Eli Lilly and Company (NYSE:LLY ) and Alkermes, Inc....
|
